Compare Amgen, Inc. (AMGN) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Corning Incorporated — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Corning Incorporated trades at $184.52 (market cap $164.29B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | GLW | |
|---|---|---|
Market Cap | $196.12B | $164.29B |
Sector | Health | Technology |
52-Week High | $388.16 | $255.79 |
52-Week Low | $271.18 | $51.60 |
Enterprise Value | $241.41B | $172.46B |
Dividend Yield | 2.77% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
GLW trades at $190.85, down 0.87% on the day, with a bullish technical signal supported by moving averages and oversold RSI-6 at 12.45. Recent earnings beats in Q3 2025-Q1 2026 and strong 2025 revenue growth to $15.63B highlight fundamental strength. Analyst consensus is bullish with a $208.60 price target, though high P/E of 91.77 raises valuation concerns. News outlets like Barron's (July 10, 2026) note AI-driven partnerships as a key catalyst amid recent volatility.
Outlook remains positive with AI infrastructure demand fueling growth, but risks include elevated debt levels and competitive pressures. The stock offers a dividend yield of approximately 0.29% with consistent payouts. Investors should weigh robust earnings momentum against rich valuations and macroeconomic headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
